title: High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: the Heparin in Early Patency (HEAP) randomized trial.
abstract: OBJECTIVE
  In the Heparin in Early Patency (HEAP) pilot study a beneficial effect of high-dose heparin on early patency in acute myocardial infarction (MI) was observed in a matched-control study.
  
  
  BACKGROUND
  High dose bolus intravenous injection of heparin may achieve lysis of coronary thrombi and could enhance early patency of the infarct related vessel in patients with MI scheduled for primary angioplasty.
  
  
  METHODS
  Before primary angioplasty, 584 patients with MI entered an open randomized trial of high dose (300 IU/kg) or low dose (0 or 5,000 IU) heparin. Of the 584 patients, 299 were randomized to high dose and 285 patients to low dose heparin.
  
  
  RESULTS
  Thrombolysis In Myocardial Infarction (TIMI) flow grade 2 or 3 was observed before primary angioplasty in 65 patients (22%) in the high dose group and 60 patients (21%) in the low dose heparin group (p > 0.1), whereas TIMI flow grade 3 was observed in 38 (13%) and 24 patients (9%), respectively (p = 0.11). There were no differences in the clinical end points between the two groups. There were no hemorrhagic strokes, while 10% of the patients in the high dose group required blood transfusion versus 6% in the low dose/no heparin group (p = 0.07). No subsets of patients showed beneficial effects of high dose heparin, such as patients with longer delay between heparin administration and diagnostic angiogram or patients with short delay between symptom onset and admission.
  
  
  CONCLUSIONS
  There is no benefit of high dose bolus heparin on early patency compared with no or low dose heparin.
authors.affiliation: Hospital De Weezenlanden, Zwolle, The Netherlands.
authors.forename: A
authors.initials: A
authors.lastname: Liem
authors.forename: F
authors.initials: F
authors.lastname: Zijlstra
authors.forename: J P
authors.initials: JP
authors.lastname: Ottervanger
authors.forename: J C
authors.initials: JC
authors.lastname: Hoorntje
authors.forename: H
authors.initials: H
authors.lastname: Suryapranata
authors.forename: M J
authors.initials: MJ
authors.lastname: de Boer
authors.forename: F W
authors.initials: FW
authors.lastname: Verheugt
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D017023:Coronary Angiography; D004562:Electrocardiography; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D012449:Safety; D013318:Stroke Volume; D015912:Thrombolytic Therapy; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D006493:Heparin